{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:54:57Z","timestamp":1790070897038,"version":"4.0.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.critrevonc.2013.01.003","type":"journal-article","created":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T01:47:36Z","timestamp":1360979256000},"page":"239-255","source":"Crossref","is-referenced-by-count":43,"title":["Targeting BRAF in melanoma: Biological and clinical challenges"],"prefix":"10.1016","volume":"87","author":[{"given":"Mario","family":"Mandal\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Voit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2013.01.003_bib0005","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"A Cancer Journal for Clinicians"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0015","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0020","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1055-9965.EPI-10-0233","article-title":"Melanocytic nevi, nevus genes, and melanoma risk in a large case\u2013control study in the United Kingdom","volume":"19","author":"Newton-Bishop","year":"2010","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0025","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0030","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0035","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1755-148X.2011.00880.x","article-title":"The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin","volume":"24","author":"Whiteman","year":"2011","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0040","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"Atkins","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0045","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0050","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.hoc.2009.03.009","article-title":"Melanoma and immunotherapy","volume":"23","author":"Eggermont","year":"2009","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0070","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0075","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1200\/JCO.1998.16.9.2921","article-title":"Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients","volume":"16","author":"Keilholz","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0080","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0959-8049(02)00123-5","volume":"38","author":"Keilholz","year":"2002","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0085","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.25156","article-title":"High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma","volume":"116","author":"Weide","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0090","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0095","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0b013e3283485ff0","article-title":"Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial","author":"Hofmann","year":"2011","journal-title":"Melanoma Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1755-148X.2010.00778.x","article-title":"Genetic and morphologic features for melanoma classification","volume":"23","author":"Broekaert","year":"2010","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0105","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/sj.onc.1210392","article-title":"Differential regulation and properties of MAPKs","volume":"26","author":"Raman","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: B-RAF is a human oncogene","volume":"6","author":"Garnett","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0115","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.8073291","article-title":"Ras-dependent growth factor regulation of MEK kinase in PC12 cells","volume":"265","author":"Lange-Carter","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0120","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/j.1460-2075.1995.tb07316.x","article-title":"Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation","volume":"14","author":"Marais","year":"1995","journal-title":"EMBO Journal"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0125","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.7992057","article-title":"Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK","volume":"266","author":"Minden","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0130","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1074\/jbc.272.7.4378","article-title":"Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases","volume":"272","author":"Marais","year":"1997","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0135","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0140","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.hoc.2009.04.001","article-title":"BRAF signaling and targeted therapies in melanoma","volume":"23","author":"Dhomen","year":"2009","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0145","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nrm1498","article-title":"The RAF proteins take centre stage","volume":"5","author":"Wellbrock","year":"2004","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc1360","article-title":"The discovery of receptor tyrosine kinases: targets for cancer therapy","volume":"4","author":"Gschwind","year":"2004","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(09)02001-6","article-title":"Ras signaling and therapies","volume":"102","author":"Young","year":"2009","journal-title":"Advances in Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signaling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cub.2005.01.031","article-title":"BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma","volume":"15","author":"Patton","year":"2005","journal-title":"Current Biology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nature Genetics"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0175","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.bjc.6603283","article-title":"Cellular senescence in naevi and immortalisation in melanoma: a role for p16?","volume":"95","author":"Gray-Schopfer","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0180","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","article-title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi","volume":"436","author":"Michaloglou","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0185","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.2353\/ajpath.2009.081057","article-title":"The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes","volume":"174","author":"Yu","year":"2009","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0190","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1101\/gad.1516407","article-title":"A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors","volume":"21","author":"Dankort","year":"2007","journal-title":"Genes and Development"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0195","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"Braf(V600E) cooperates with Pten loss to induce metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nature Genetics"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0200","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":"Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma","volume":"126","author":"Goel","year":"2006","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0205","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1038\/onc.2008.258","article-title":"C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells","volume":"27","author":"Zhuang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0210","first-page":"5198","article-title":"Suppression of BRAF (V599E) in human melanoma abrogates transformation","volume":"63","author":"Hingorani","year":"2003","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0215","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1479-5876-7-86","article-title":"Main roads to melanoma","volume":"7","author":"Palmieri","year":"2009","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0220","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CCO.0b013e32833888ee","article-title":"Mutation-driven drug development in melanoma","volume":"22","author":"Flaherty","year":"2010","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0225","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0230","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0235","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ng.810","article-title":"Exome sequencing identifies GRIN2A as frequently mutated in melanoma","volume":"43","author":"Wei","year":"2011","journal-title":"Nature Genetics"},{"issue":"June","key":"10.1016\/j.critrevonc.2013.01.003_bib0240","first-page":"941","article-title":"Improving melanoma classification by integrating genetic and morphologic features","volume":"5","author":"Viros","year":"2008","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0250","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0255","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0260","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0265","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0270","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0275","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0280","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/bjc.2011.239","article-title":"Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?","volume":"105","author":"Sigalotti","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0285","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients","volume":"30","author":"Colombino","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0290","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","article-title":"Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis","volume":"95","author":"Eisen","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0295","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0300","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8511","article-title":"Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin \u00a9\/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma","volume":"28","author":"Flaherty","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0305","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0310","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1073\/pnas.1008990107","article-title":"The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner","volume":"107","author":"Joseph","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0315","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0320","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0325","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0330","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncology"},{"issue":"Dec","key":"10.1016\/j.critrevonc.2013.01.003_bib0335","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","author":"Klein","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0340","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8501","article-title":"Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436)","volume":"29","author":"Nathanson","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0345","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0350","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","article-title":"Phase II open-label randomized trial of the MEK1\/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma","volume":"18","author":"Kirkwood","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0355","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8501","article-title":"Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma","volume":"28","author":"Patel","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0360","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.2503","article-title":"Safety and efficacy results from the first-in-human study of the oral MEK 1\/2 inhibitor GSK1120212","volume":"28","author":"Infante","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"December","key":"10.1016\/j.critrevonc.2013.01.003_bib0365","article-title":"Phase II Study of the MEK1\/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor","author":"Kim","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0370","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0375","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-09-1883","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK\/ERK kinase inhibitor PD-0325901 in patients with advanced cancers","volume":"16","author":"LoRusso","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0380","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.2504","article-title":"First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors","volume":"28","author":"Delord","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0385","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.18_suppl.cra8503","article-title":"Phase I\/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1\/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)","volume":"29","author":"Infante","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0390","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0395","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0400","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0405","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0410","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0415","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0420","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0425","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CCO.0b013e32834fca92","article-title":"Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights","volume":"24","author":"Dummer","year":"2012","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0430","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/0008-5472.CAN-11-0140","article-title":"Combinatorial treatments that overcome PDGFR\u03b2-driven resistance of melanoma cells to V600EB-RAF inhibition","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0435","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1755-148X.2011.00950.x","article-title":"Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition","volume":"25","author":"Deng","year":"2012","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0440","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0445","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/onc.2011.250","article-title":"Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF","volume":"31","author":"Xing","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0450","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1073\/pnas.0609973103","article-title":"V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors","volume":"103","author":"Grbovic","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0455","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1158\/0008-5472.CAN-05-2632","article-title":"Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin","volume":"65","author":"da Rocha Dias","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0460","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-11-2612","article-title":"The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms","volume":"18","author":"Paraiso","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0465","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1541-7786.MCR-06-0077","article-title":"Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression","volume":"4","author":"Kono","year":"2006","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0470","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0475","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0480","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1158\/1078-0432.CCR-10-1911","article-title":"The oncogenic BRAF kinase inhibitor PLX4032\/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations","volume":"16","author":"Comin-Anduix","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.01.003_bib0485","article-title":"Phase IB study of Vemurafenib in combination with the MEK inhibitor GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7)","author":"Gonzalez","year":"2012","journal-title":"ESMO"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T20:25:13Z","timestamp":1562703913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1040842813000292"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.01.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}